ClinicalTrials.gg
Status unknownNCT04413227Updated Jun 2, 2020

A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors

A Phase 1 interventional study of Pegylated Recombinant Human Endostatin(PEG-ENDO) in NSCLC and Solid Tumor, sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd.. Status unknown at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-06-02.

Sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd. (part of Simcere Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The primary purpose of this study is to examine the safety, tolerability and pharmacokinetics of PEG-ENDO in combination with docetaxel in subjects previously treated or untreated (standard therapy is not suitable or without standard therapy) for advanced or metatatic non-small cell lung cancer (NSCLC) or other solid tumors.

Read the detailed description

This is a multicenter, open-label, dose-escalation study in subjects with advanced or metatatic non-small cell lung cancer (NSCLC) or other solid tumors.There will be five cohorts planning as following:

cohort 1: PEG-ENDO 1 mg/kg+Docetaxel 75 mg/m2,once every 3 weeks at day 1 cohort 2: PEG-ENDO 2mg/kg+Docetaxel 75 mg/m2,once every 3 weeks at day 1 cohort 3: PEG-ENDO 4 mg/kg+Docetaxel 75 mg/m2,once every 3 weeks at day 1 cohort 4: PEG-ENDO 6 mg/kg+Docetaxel75 mg/m2,once every 3 weeks at day 1 cohort 5: PEG-ENDO 8 mg/kg+Docetaxel75 mg/m2, once every 3 weeks at day 1

* Every 3 weeks as a treatment cycle. Subjects received only PEG-ENDO in the first cycle. For second cycle or the higher, they received a combination therapy of PEG-ENDO and docetaxel. Docetaxel was limited in 4 or 6 cycles。 The observation period of DLT was the 21 days after the first administration of PEG-ENDO. During the observation period of DLT (cycle 1), subjects only receive the corresponding dose of PEG-ENDO , for the second cycle and higher ,they will treated with the combination of PEG-ENDO and Docetaxel until disease progression (PD) or intolerance . Docetaxel was limited in 4 or 6 cycles。

02

Conditions studied

  • NSCLC
  • Solid Tumor

Keywords

  • pegylated recombinant human endostatin (PEG-ENDO)
03

In context

Lead sponsor

Jiangsu Simcere Pharmaceutical Co., Ltd. is the lead sponsor of 78 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated, written .
  2. 18-70years old, male or female.
  3. Histological or cytological confirmation diagnosis of Non Small Cell Lung Cancer(NSCLC) or other solid tumor, previous treated with standard therapy , or standard therapy not suitabl ,or without standard therapy.
  4. At least one according to v1.1.
  5. of at least 3 months.
  6. (ECOG) performance score 0 or 1.
  7. Demonstrate adequate organ function -

Exclusion criteria

Exclusion Criteria:

  1. uncontrolled primary CNS tumors, , or meningeal .
  2. Evidence of a tumor that compresses or invades major blood vessels.
  3. History of hemoptysis (>1/2 teaspoon per event) or severe bleeding or evidence of bleeding disorders in the last 3 months.
  4. active cardiovascular disease within 6 months prior to planned start of PEG-ENDO.
  5. Prior treatment with anti-agiogenetic agent.
  6. Pregnant female patients; breastfeeding female patients.

    -

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    PEG-ENDO+Docetaxel

    PEG-ENDO( 1 mg/kg or 2mg/kg or 4mg/kg or 6mg/kg or 8mg/kg)+Docetaxel 75 mg/m2,once every 3 weeks at day 1

    Drug: Pegylated Recombinant Human Endostatin(PEG-ENDO)

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicities (DLT)

    Incidence of Dose Limiting Toxicity

    Time frame: First 21days for dosing(Cycle1,each cycle is 21 days)

  2. Adverse Event(AE)

    Incidence of Adverse Events

    Time frame: From the time the subjects signed the Informed Consent Form to 28 days after the end of the study drug treatment

  3. Serious Adverse Event(SAE)

    Incidence of Serious Adverse Events

    Time frame: From the subjects signed the Informed Consent Form to 28 days after the end of the study drug treatment

  4. Laborarory test abnormality

    Incidence of clinically significant laboratory abnormalities

    Time frame: From the subjects signed the Informed Consent Form to 28 days after the end of the study drug treatment

  5. Vital signs abnormality

    Incidence of vital signs abnormalities

    Time frame: From the subjects signed the Informed Consent Form to 28 days after the end of the study drug treatment

  6. Electrocardiogram(ECG) abnormality

    Incidence of clinically significant ECG abnormalities

    Time frame: From the subjects signed the Informed Consent Form to 28 days after the end of the study drug treatment

  7. Serum concentration

    Serum concentration of PEG-ENDO

    Time frame: Pharmacokinetics(PK) blood samples are collected at pre-dose, post-dose 0,1,4,8,24,48,96,168,336,480h of cycle1 and cycle5,respectively. And the pre-dose, post-dose 0h of other required cycles.

  8. The maximum (or peak) serum ,Cmax

    Cmax of PEG-ENDO following dose concentration.

    Time frame: Pharmacokinetics(PK) blood samples are collected at pre-dose, post-dose 0,1,4,8,24,48,96,168,336,480h of cycle1 and cycle5,respectively. And the pre-dose, post-dose 0h of other required cycles.

  9. AUC

    The area under the plot of serum concentration of drug (not logarithm of the concentration) against time after drug administration.

    Time frame: Pharmacokinetics(PK) blood samples are collected at pre-dose, post-dose 0,1,4,8,24,48,96,168,336,480h of cycle1 and cycle5,respectively. And the pre-dose, post-dose 0h of other required cycles.

  10. other PK parameters

    The other PK parameters (if applicable).

    Time frame: Pharmacokinetics(PK) blood samples are collected at pre-dose, post-dose 0,1,4,8,24,48,96,168,336,480h of cycle1 and cycle5,respectively. And the pre-dose, post-dose 0h of other required cycles.

  11. Maximum Tolerated Dose(MTD)

    To determine the Maximum Tolerated Dose (MTD) of PEG-ENDO in subjects with Advanced / Metastatic NSCLC or Other Solid Tumors

    Time frame: First 21days for dosing(Cycle1,each cycle is 21 days)

Secondary outcomes

  1. Overall Response Rate(ORR)

    ORR is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) assessment in accordance to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)

    Time frame: at least 12 weeks

  2. Duration of Response(DOR)

    DOR is defined as the time from first documented response (PR or CR) to the date of first documented disease progression or death due to any cause determined by Investigator assessment in accordance to RECIST 1.1

    Time frame: Estimated at 4 months after fist documented PD or CR

  3. Progression-free survival (PFS)

    PFS is defined as time from date of first dose of study treatment to date of first documented disease progression or death due to any cause determined by by Investigator assessment in accordance to RECIST 1.1

    Time frame: Estimated at 4 months.

07

Study locations

1 of 2 sites recruiting
  • Beijing Hospital
    Beijing, Beijing 100005, China
    Not yet recruiting
  • Tianjin medical university cancer institute&hospital
    Tianjin, Tianjin 300060, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2020 (actual). Primary completion is estimated for May 2021, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2020
First posted
Jun 2, 2020
StartActual
Apr 2, 2020
Primary completionEst.
May 31, 2021
CompletionEst.
Sep 30, 2021
Last update
Jun 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04413227
Responsible party
Sponsor
First posted
Jun 2, 2020
Start date
Apr 2, 2020
Primary completion
May 31, 2021 (estimated)
Completion
Sep 30, 2021 (estimated)
Last update
Jun 2, 2020

Study contacts

Huang Dingzhi, Ph.D
Contact
dingzhih72@163.com
02223340123 ext. 3220
Huang Dingzhi, Ph.D
principal investigator · Tianjin Medical University Cancer Institute and Hospital
Li Lin, Ph.D
principal investigator · Beijing Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Docetaxel

Start the discussion